Zacks Small-Cap Research

June 19, 2017
David Bautz, PhD
312--2659471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Viking Therapeutics, Inc. (VKTX-NASDAQ)

VKTX: Raises $4.3 Million in Gross Proceeds From Registered Direct Offering…

Based on our probability adjusted DCF model that takes into account potential future revenues of VK5211, VK2809, and VK0214, VKTX is valued at $7/share. This model is highly dependent upon continued clinical success of those compounds and will be adjusted accordingly based upon future clinical results.

Current Price (06/19/17)	$1.26
Valuation	**$7.00**

OUTLOOK

On June 14, 2017, Viking Therapeutics, Inc. announced it raised approximately $4.3 million in gross proceeds from a registered direct offering of its common stock. The company sold approximately 3.7 million shares of common stock along with approximately 2.8 million warrants to purchase one share of common stock at an exercise price of $1.30 per share. The combined purchase price for one share of common stock and one warrant to purchase 0.75 shares of common stock was $1.15.

We remind investors that data from the company's Phase 2 trial of VK5211 in hip fracture is due at the end of the summer 2017 and data from a Phase 2 study of VK2809 in patients with fatty liver disease are expected in the fourth quarter of 2017.

SUMMARY DATA

52-Week High	**$1.69**
52-Week Low	**$0.95**
One-Year Return (%)	**-18.80**
Beta	**1.07**
Average Daily Volume (sh)	**165,052**
Shares Outstanding (mil)	**28**
Market Capitalization ($mil)	**$30**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**3**
Insider Ownership (%)	**8**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2016 Estimate	**-0.9**
P/E using 2017 Estimate	**-1.1**

Risk Level	**High,**
Type of Stock	**Small-Blend**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(In millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2016	0 A	0 A	0 A	0 A	0 A
2017	0 A	0 E	0 E	0 E	0 E
2018					0 E
2019					0 E

Earnings per Share
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2016	-$0.40 A	- $0.22 A	-$0.20 A	-$0.18 A	-$0.90 A
2017	-$0.23 A	-$0.16 E	-$0.16 E	-$0.16 E	-$0.70 E
2018					-$0.63 E
2019					-$0.65 E

© Copyright 2017, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Financial Update

On June 14, 2017, Viking Therapeutics, Inc. (VKTX) announced it raised gross proceeds of $4.3 million from a registered direct offering. The purchase price for one share of common stock and one warrant to purchase 0.75 shares of common stock was $1.15. Viking sold approximately 3.7 million shares of its common stock and warrants to purchase approximately 2.8 million shares of its common stock. The warrants are exercisable six months following the date of issuance at a price of $1.30 and will expire in five years.

This financing will help to cushion the balance sheet, which we believe will be important for partnering negotiations for VK5211 after the results of the Phase 2 clinical trial are announced in late summer 2017. In addition, it extends the cash runway a bit further into the first half of 2018. Lastly, it removes most of stock available through the distribution agreement with Maxim, which may have been weighing on the stock.

Business Update

On June 6, 2017, Viking Therapeutics, Inc. (VKTX) announced promising results from an *in vivo* study of VK2809 in a mouse model of diet-induced non-alcoholic steatohepatitis (NASH). Animals treated with VK2809 had statistically significant reductions in a number of key measures related to the development and progression of NASH, including liver triglyceride content, liver cholesterol content, liver fibrosis, liver collagen content, and liver hydroxyproline content. VK2809 also performed better (though not all reached statistical significance) in those parameters than an undisclosed active control, which is a metabolic-targeting agent currently in late-stage development. These data are the first to demonstrate a histological benefit from a thyromimetic agent in a NASH model. We continue to expect data from a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease in the fourth quarter of 2017.

Diet-Induced Mouse Model of NASH

Several animal models have been developed to represent the various pathophysiologic changes, morphologic changes, biochemical changes, and clinical features of NASH (Sanches *et al*., 2015). These models can be classified as nutritional (diet-induced), genetic, or a combination of nutritional and genetic. A robust model should recapitulate all of the hallmarks of the disease, including changes in metabolic profile, steatosis, inflammation, hepatocellular ballooning, fibrosis, and tumor susceptibility. The genetic models are typically best at inducing biochemical changes seen in NASH (e.g., increases in liver triglyceride and cholesterol), while the different nutritional models typically result in histopathological changes that are consistent with NASH, but lack the biochemical changes. The following chart shows the different animal models currently utilized to study NASH, with the fructose/high-fat diet-induced model best able to recapitulate the main clinical features (CF), biochemical changes (BC), morphological findings (MF), and the occurrence of NASH. We believe it is important for investors to understand that there are a number of different NASH models, thus while some compounds may show robust activity in a certain NASH model, if that model does not best represent what is seen in the clinic it is likely of little use.



Source: Sanches *et al*., 2015

Viking utilized a mouse model of NASH using wild-type mice fed a diet that consisted of 40% fat (18% trans fat), 40% carbohydrate (20% fructose), and 2% cholesterol (Clapper *et al*., 2013). This diet has previously been shown to induce steatosis, steatohepatitis with fibrosis, and cirrhosis and mimics what may be seen in individuals with poor dietary habits. Following 33 weeks on the diet, a biopsy was performed to confirm the presence of disease characteristics, including fibrosis. Mice were then treated for eight weeks with VK2809 (10 mg/kg/day), vehicle control, or an undisclosed active control that is in late-stage clinical development for NASH. Results from a study using this same model to examine the effects of treatment with liraglutide, elafibranor, and obeticholic acid were recently presented (Feigh *et al*., 2017), thus we believe the active comparator may be one of those compounds.

VK2809 Shows Robust Activity in NASH Model

While we will have to wait for the full data set to be presented later this year at a scientific conference, the preliminary data that Viking disclosed is quite impressive. The following table shows the results obtained with VK2809 compared to both vehicle control and active control. For all parameters, VK2809 performed statistically significantly better than vehicle control. Compared to active control, VK2809 was statistically significantly better than for liver triglyceride and liver cholesterol content, and there were clear trends toward significance for liver collagen and hydroxyproline. A recent presentation showed that liver collagen significantly correlated with fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), a precursor to NASH (Buzzetti *et al*., 2017). Fibrosis is a known risk-factor for adverse outcomes in patients with NAFLD (Angulo *et al*., 2015).

Parameter	VK2809 Compared to Vehicle Control	*P* value	VK2809 Compared to Active Control	*P* value
Liver Triglycerides	↓ 70%	<0.0001	↓ 56%	<0.0001
Liver Cholesterol	↓ 65%	<0.0001	↓ 58%	<0.0001
Liver Fibrosis	↓ 50%	0.01	↓ 21%	0.3
Liver Collagen	↓ 60%	<0.005	↓ 49%	0.07
Liver Hydroxyproline	↓ 46%	0.01	↓ 36%	0.06

Source: Viking Therapeutics, Inc. / Zacks SCR

VK2809 was also superior in a number of other outcomes. Animals treated with VK2809 experienced a 40% mean improvement in non-alcoholic fatty liver disease activity score (NAS; a composite measure of disease activity that is comprised of steatosis, ballooning, and inflammation) compared to animals treated with vehicle (P<0.0001). Fifty percent of VK2809-treated animals improved by at least two points in NAS, compared to no vehicle-treated animals (P=0.01), and no animals treated with VK2809 experienced a worsening in NAS while 60% of vehicle-treated animals did (P<0.0001). Lastly, there were no unexpected or abnormal laboratory findings for VK2809-treated animals and all animals received all scheduled doses of drug.

VK2809 Phase 2 Clinical Trial

Viking is currently conducting a Phase 2 clinical trial of VK2809 as a treatment for both hypercholesterolemia and fatty liver disease. The company is enrolling patients with elevated cholesterol, fatty liver disease, and at least three risk factors for metabolic syndrome, which is considered a major driver for the onset of NASH. The primary endpoint will assess changes in LDL following 12 weeks of treatment, with exploratory endpoints evaluating changes in liver fat content, inflammatory markers, and histological changes. Upon conclusion, the company hopes to be in a position to move forward in either hypercholesterolemia or NASH. Thus, it could be viewed as a two-in-one study – confirmatory on LDL and exploratory for fatty liver disease. We anticipate topline results in the fourth quarter of 2017.

Conclusion

As a reminder, Viking is expected to announce additional results from a long-term *in vivo* study of VK0214 in a model of X-linked adrenoleukodystrophy (X-ALD) in the second quarter of 2017, and results from the Phase 2 study of VK5211 in hip fracture in late summer 2017.

The preliminary data regarding VK2809 in a diet-induced model of NASH are very encouraging, particularly since the compound was better than another drug in late stage clinical trials for NASH in a number of different parameters. We hope to learn the identity of the active comparator later in the year when the company presents the full data set at a scientific conference. Results from the ongoing Phase 2 clinical trial of VK2809 in hypercholesterolemia and fatty liver disease are expected in the fourth quarter of 2017, and if those results are similar to what was seen in the *in vivo* model, then the company's valuation is likely to increase significantly from what is now a perplexingly low $25 million. Our current valuation is $7/share.

PROJECTED FINANCIALS

Viking Therapeutics, Inc.
Income Statement

Viking Therapeutics, Inc.	2016 A	Q1 A	Q2 E	Q3 E	Q4 E	2017 E	2018 E	2019 E
VK5211 (Hip Fracture)	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-
VK2809 (Hypercholesterolemia)	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-
VK0214 (ALD)	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-
Grants & Collaborative Revenue	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-
Total Revenues	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**
YOY Growth	-	-	-	-	-	-	-	-
Cost of Sales	$0	$0	$0	$0	$0	$0	$0	$0
Product Gross Margin	-	-	-	-	-	-	-	-
Research & Development	$9.0	$3.5	$2.5	$2.6	$2.8	$11.4	$14.0	$16.0
General & Administrative	$4.8	$1.4	$1.2	$1.2	$1.2	$5.0	$5.0	$6.0
Other Expenses	$0	$0	$0	$0	$0	$0	$0	$0
Operating Income	($13.8)	($5.0)	($3.7)	($3.8)	($4.0)	($16.5)	($19.0)	($22.0)
Operating Margin	-	-	-	-	-	-	-	-
Non-Operating Expenses (Net)	($0.9)	($0.3)	($0.1)	($0.1)	($0.1)	($0.6)	($0.5)	($0.6)
Pre-Tax Income	($14.7)	($5.2)	($3.8)	($3.9)	($4.1)	($17.0)	($19.5)	($22.6)
Income Taxes Paid	($0)	$0	$0	$0	$0	$0	$0	$0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net Income	**($14.7)**	**($5.2)**	**($3.8)**	**($3.9)**	**($4.1)**	**($17.0)**	**($19.5)**	**($22.6)**
Net Margin	-	-	-	-	-	-	-	-
Reported EPS	**($0.90)**	**($0.23)**	**($0.16)**	**($0.16)**	**($0.16)**	**($0.70)**	**($0.63)**	**($0.65)**
YOY Growth	-	-	-	-	-	-	-	-
Basic Shares Outstanding	16.278	22.353	23.500	25.000	26.000	24.213	31.000	35.000

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

© Copyright 2017, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE



© Copyright 2017, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.